drugset / Trial / NCT04580745

Study of MORF 057 to Evaluate Single and Multi Ascending Doses in Healthy Volunteers

NCT04580745

Phase 1 Completed 67 enrolled Eli Lilly and Company
RandomizedSequentialDouble-blindOther

Summary

Phase 1a randomized, double-blind, placebo-controlled study to evaluate single and multiple ascending doses of MORF-057 in healthy subjects.

Timeline

Start
2020-09-23
Primary completion
2021-03-31
Completion
2021-04-12

Drugs

EvaluationDrugModalityDoseRoute
Subject LY4268989 Unknown Oral

Indications

No indication recorded.